title: [Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study].
abstract: OBJECTIVE
  To determine the clinical toxicities and antitumor effects of a chemotherapy regimen of FTQ, a compound preparation of tegafur, the drug prototype of 5-furacil (5-FU), gimeracil (CDHP), a decomposition inhibitor of 5-FU, oteracil potassium, phosphorylation inhibitor of 5-FU, and combined with cisplatin in patients with inoperable locally or metastatic advanced gastric cancer.
  
  
  METHODS
  119 patients with inoperable locally or metastatic advanced gastric cancer admitted in 10 hospitals in China were divided into 2 groups: FTQ group (n = 59), undergoing a 3-week regime, i.e. oral use of 80 mg x m(-2) x d(-1) for 14 d and then discontinuance for 1 week and intravenous drip cisplatin 75 mg/m2 on days 1-3; and control group (n = 60) undergoing a 3-week regimen including oral use of tegafur 800 mg x m(-2) x d(-1) tid for 14 d and then discontinuance for 1 week and intravenous drip of cisplatin 75 mg/m2 on days 1-3. The curative was evaluated after at least after 2 regimens.
  
  
  RESULTS
  There were 102 patients in the per-protocol population. The overall response rate of the FTQ group was 28. 3% (15/53), significantly higher than that of the control group (4.1%, 2/49, P = 0.004). The clinical improvement of the FTQ group was 50.9%, significantly higher than that of the control group (24.5%, P = 0.006). The main toxicities occurred in bone marrow and the digestive tract. The leucopenia and thrombocytopenia rates of the FTQ group were 47.45% and 32.22% respectively, both similar to those of the control group. There were no differences in the incidence rate of digestive canal side reaction between these 2 groups .
  
  
  CONCLUSIONS
  The regimen of FTQ combined with cisplatin is generally well-tolerated and has substantial antitumor activity.
authors.affiliation: Department of Oncology, General Hospital of People's Liberation Army, Beijing 100853, China.
authors.forename: Jun-lan
authors.initials: JL
authors.lastname: Yang
authors.forename: Shun-chang
authors.initials: SC
authors.lastname: Jiao
authors.forename: Guang-hai
authors.initials: GH
authors.lastname: Dai
authors.forename: Fang
authors.initials: F
authors.lastname: Li
authors.forename: Hong
authors.initials: H
authors.lastname: Zhao
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
authors.forename: Jian-ming
authors.initials: JM
authors.lastname: Xu
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
authors.forename: Yang
authors.initials: Y
authors.lastname: Zhang
authors.forename: Run-gui
authors.initials: RG
authors.lastname: Niu
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Xie
authors.forename: Shu-ping
authors.initials: SP
authors.lastname: Song
authors.forename: Feng-chun
authors.initials: FC
authors.lastname: Zhang
authors.forename: Hui-shan
authors.initials: HS
authors.lastname: Lu
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D016037:Single-Blind Method; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D011725:Pyridines; D005641:Tegafur; C489337:potassium oxonate; D010094:Oxonic Acid; D002945:Cisplatin; D005472:Fluorouracil; C104201:gimeracil